Thomas K. Equels Acquires 60,110 Shares of AIM ImmunoTech Inc. (NYSE:AIM) Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels purchased 60,110 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were purchased at an average cost of $0.18 per share, with a total value of $10,819.80. Following the completion of the acquisition, the chief executive officer now owns 1,552,968 shares in the company, valued at $279,534.24. The trade was a 4.03 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

AIM ImmunoTech Stock Performance

AIM ImmunoTech stock opened at $0.20 on Thursday. AIM ImmunoTech Inc. has a 52-week low of $0.16 and a 52-week high of $0.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a 50 day moving average price of $0.26 and a two-hundred day moving average price of $0.33.

Analyst Upgrades and Downgrades

AIM has been the subject of a number of recent analyst reports. Ascendiant Capital Markets cut their target price on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Maxim Group cut their price objective on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, October 22nd.

Institutional Investors Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC bought a new stake in AIM ImmunoTech Inc. (NYSE:AIM) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is currently owned by institutional investors and hedge funds.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).